共查询到20条相似文献，搜索用时 67 毫秒
1.
2.
HPLC法检测磺胺间甲氧嘧啶钠和甲氧苄啶方法的研究 总被引：1，自引：0，他引：1
采用HPLC法同时测定复方磺胺间甲氧嘧啶钠蜂胶溶液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量.色谱柱为Kromasil C18柱(250×4.6 mm,粒径5 μm),流动相为0.02 mol/L磷酸溶液-甲醇(80∶20,V/V),检测波长270 nm,流速1.0 mL/min,柱温30 ℃.在10～500 μg/mL浓度范围内,磺胺间甲氧嘧啶钠和甲氧苄啶均呈线性关系.平均回收率分别为99.3%和99.4%.该法准确可行,适用于同时检测复方磺胺间甲氧嘧啶钠蜂胶溶液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量. 相似文献
3.
利用高效液相色谱法(HPLC)同时测定复方磺胺间甲氧嘧啶钠注射液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量。采用C18柱(5μm, 4.6 mm×250.0 mm),以乙腈∶0.1%磷酸溶液(20∶80,V/V)为流动相，检测波长230 nm,柱温30℃,流速1.0 mL/min。结果表明，磺胺间甲氧嘧啶在5.00～200.00μg/mL浓度范围内与峰面积线性关系良好(R2=0.999 6),平均回收率为99.49%,RSD为0.18%;甲氧苄啶在1.00～50.00μg/mL浓度范围内与峰面积线性关系良好(R2=0.999 7),平均回收率为99.02%,RSD为0.60%。本方法简单快捷，精密度好，可用于控制复方磺胺间甲氧嘧啶钠注射液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量。 相似文献
4.
HPLC法同时检测复方磺胺间甲氧嘧啶钠溶液中磺胺间甲氧嘧啶钠和甲氧苄啶 总被引：1，自引：1，他引：0
采用HPLC法同时测定复方磺胺间甲氧嘧啶钠溶液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量。色谱柱为Kromasil C18柱(250 mm×4.6 mm,粒径5μm),流动相为0.02 mol/L磷酸溶液-甲醇(80∶20,V/V),检测波长270 nm,流速1.0 mL/min,柱温30℃。在10~500μg/mL浓度范围内,磺胺间甲氧嘧啶钠和甲氧苄啶均呈线性关系。平均回收率分别为99.25%和99.76%。该法准确可行,适用于同时检测复方磺胺间甲氧嘧啶钠溶液中磺胺间甲氧嘧啶钠和甲氧苄啶的含量。 相似文献
5.
6.
建立了兽用复方磺胺对甲氧嘧啶片含量测定的高效液相色谱法(HPLC)。试验采用C18色谱柱,0.1%磷酸-乙腈(85∶15)为流动相,流速为1.0 mL/min,进样量20μL,测定波长240 nm,柱温40℃。采用外标法定量计算磺胺对甲氧嘧啶和甲氧苄啶的含量。结果表明,磺胺对甲氧嘧啶在30～300μg/mL浓度范围内,其峰面积与浓度呈良好的线性关系(R~2=1),平均回收率为99.3%;甲氧苄啶在6～60μg/mL浓度范围内,其峰面积与浓度呈良好的线性关系(R~2=1),平均回收率为99.0%。HPLC方法有良好的精密度、稳定性,能够用于测定兽用复方磺胺对甲氧嘧啶片各成分的含量,对该片剂的质量控制起到重要作用。 相似文献
7.
为了验证同时测定复方磺胺氯吡嗪钠可溶性粉中磺胺氯吡嗪钠和甲氧苄啶含量的HPLC法,试验以Agilent C18柱为色谱柱,0.1%磷酸溶液(三乙胺调节pH值至4.0)-乙腈(80∶20)为流动相,流速为1.0 mL/min,检测波长为271 nm,柱温为35℃的条件建立了同时检测复方磺胺氨氯吡嗪钠可溶性粉有效成分含量的HPLC法,并进行方法的方法学验证试验,对样品含量进行实测。结果表明:磺胺氯吡嗪钠在30.1～61.9μg/mL,甲氧苄啶在6.1～194.3μg/mL范围内,浓度与其相应峰面积呈良好线性关系,R~2分别为1.000和0.999 9。精密度试验RSD分别为0.04%和0.08%。重复性试验RSD分别为0.29%和0.09%。稳定性试验RSD分别为0.31%和0.18%。平均加样回收率分别为99.4%和98.8%。样品中实测磺胺氯吡嗪钠和甲氧苄啶的平均含量分别为102.16%和102.68%。说明建立的测定复方制剂中磺胺氯吡嗪钠和甲氧苄啶含量的方法简单快速、重现性好、准确度高。 相似文献
8.
建立了同时测定兽药复方磺胺间甲氧嘧啶预混剂中磺胺间甲氧嘧啶及甲氧苄啶含量的高效液相色谱法。以C18柱为固定相,0.1%磷酸溶液－乙腈(86：14)为流动相,流速为1.0mL/min,柱温40℃,检测波长为240nm,采用外标法进行定量。磺胺间甲氧嘧啶的线性范围为5.02~100.36μg/mL,回归方程为Area =0.62 × Amt-0.428 (n=5),r2=0.9996;甲氧苄啶的线性范围为1.01~20.28 μg/mL,回归方程为Area =1.058 × Amt-0.075,r2 = 0.9995。取复方磺胺间甲氧嘧啶预混剂,按磺胺间甲氧嘧啶和甲氧苄啶含量的100%作添加回收实验,分别作8个平行,测得磺胺间甲氧嘧啶的回收率为98.83%~101.95%,RSD为0.91%;甲氧苄啶的回收率为99.02%~103.09%,RSD为1.23%。该方法简单,准确,精密度好,回收率高,可以用于测量复方磺胺间甲氧嘧啶预混剂的含量。 相似文献
9.
为了建立同时测定复方磺胺间甲氧嘧啶钠粉中磺胺间甲氧嘧啶钠和甲氧苄啶的高效液相色谱方法,试验采用了ECOSIL 120-5-C18（250 mm×4.6 mm,5.0 μm）色谱柱,以乙腈-0.1％磷酸溶液（20：80,V/V）为流动相进行洗脱,流速为1.0 mL/min,检测波长为270 nm,柱温为30℃,进样量为20 μL。结果表明,磺胺间甲氧嘧啶钠和甲氧苄啶色谱峰峰型良好,均能达到完全分离;且在0.5～80 μg/mL范围内线性关系良好（R2>0.999）。精密度和稳定性等考察结果的相对标准偏差（RSD）均小于2.0％;而平均加样回收率均在98％～102％之间,RSD均小于2.0％,均符合方法学要求。采用建立的高效液相色谱法测定了5份供试品中磺胺间甲氧嘧啶钠和甲氧苄啶的含量,结果均符合规定,且与原质量标准方法的测定结果无显著性差异。建立的高效液相色谱法能够用于定量测定磺胺间甲氧嘧啶钠和甲氧苄啶的含量。 相似文献
10.
为建立兽药复方磺胺嘧啶钠注射液含量测定的高效液相色谱测定法。采用流动相为0.1%的磷酸溶液-乙腈(85:15,V∶V),色谱柱为C18柱,柱温为40℃,流速为1.0 mL/min,检测波长为240 nm。采用外标法进行定量。磺胺嘧啶钠的线性范围为12.5～200μg/mL,线性方程为Y=44.873X+11.999,r~2=1.000;甲氧苄啶的线性范围为2.5～40μg/mL,线性方程为Y=62.288X+4.0826,r~2=1.000,方法的线性关系良好,添加回收率均大于98%,RSD均小于2%。结果显示该方法简单、精确、可操作,可以用于测量复方磺胺嘧啶钠注射液中磺胺嘧啶钠与甲氧苄啶的含量。 相似文献
11.
采用湿法制粒、流化床包衣制备肠溶释放微粒,正交法进行工艺参数的筛选,通过溶出度试验对其释放特性进行考察,筛选出最佳生产工艺.在此优化工艺条件下制得的微粒体外释放特性良好,在人工胃液中几乎不溶,而在人工肠液中释放达到70％以上.本品处方合理,制备工艺简单,达到了肠溶释放的目的,为恩诺沙星制剂的优化提供了依据. 相似文献
12.
恩诺沙星在鹅体内的药代动力学研究 总被引：1，自引：0，他引：1
本文对恩诺沙星在鹅体内的药动学特征进行了研究,36只鹅随机分为2组,A组静脉注射恩诺沙星溶液;B组口服恩诺沙星溶液,给药剂量均为10mg/kg体重。数据采用DAS2.0进行分析。试验结果显示,静脉注射组多项药动学参数与口服组相比存在较显著差异,静脉注射组AUC约为口服组的1.3倍,在其体内清除率仅为口服组的3/5,但在体内消除却较快,平均驻留时间仅为口服组的7/10,结合恩诺沙星对常见敏感菌的MIC参数考虑,可以认为,口服10mg/kg剂量可以满足临床养殖中抗敏感细菌感染的要求。 相似文献
13.
The pharmacokinetics of enrofloxacin (EFL) and its active metabolite ciprofloxacin (CIP) was investigated in 7-8 month old turkeys (6 birds per sex). EFL was administered intravenously (i.v.) and orally (p.o.) at a dose 10 mg kg(-1) body weight. Blood was taken prior to and at 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 h following drug administration. The concentrations of EFL and CIP in blood serum were determined by high-performance liquid chromatography (HPLC). Serum concentrations versus time were analysed by a noncompartmental analysis. The elimination half-live and the mean residence time of EFL after i.v. injection for the serum were after oral administration 6.64+/-0.90 h, 8.96+/-1.18 h and 6.92+/-0.97 h, 11.91+/-1.87 h, respectively. After single p.o. administration, EFL was absorbed slowly (MAT=2.76+/-0.48 h) with time to reach maximum serum concentrations of 6.33+/-2.54 h. Maximum serum concentrations was 1.23+/-0.30 microg mL(-1). Oral bioavailability for for EFL after oral administration was found to be 69.20+/-1.49%. The ratios C(max)/MIC and AUC(0 --> 24)/MIC were respectively from 161.23+/-5.9 h to 12.90+/-0.5 h for the pharmacodynamic predictor C(max)/MIC, and from 2153.44+/-66.6 h to 137.82+/-4.27 h for AUC(0 --> 24)/MIC, for the different clinically significant microorganisms, whose values for MIC varies from 0.008 microg L(-1) to 0.125 microg mL(-1). 相似文献
14.
依据被测物质在特定波长处的发光强度与物质质量浓度呈正比的关系,应用紫外分光光度法测定恩诺沙星原料中恩诺沙星的含量。恩诺沙星的检测波长为271 nm,与高氯酸滴定法做比较,表明本法可有效消除基体影响。具有操作简便,快速准确等特点,适用于原料药质量快速检验。 相似文献
15.
双波长紫外分光光度法测定复方恩诺沙星可溶性粉中恩诺沙星和盐酸多西环素的含量 总被引：6，自引：0，他引：6
建立了复方恩诺沙星可溶性粉中恩诺沙星和盐酸多西环素含量的检测方法.采用双波长紫外分光光度法,直接测定两组分的含量.结果显示可同时测出复方恩诺沙星可溶性粉中恩诺沙星和盐酸多西环素的各自含量,且吸收度与各自的浓度成良好线性关系.恩诺沙星平均回收率为100.1%,RSD为0.04%(n=5).盐酸多西环素平均回收率为100.2%,RSD为0.14%(n=5).本方法简便、快速、可靠,可用于复方恩诺沙星可溶性粉的含量测定. 相似文献
16.
为获得恩诺沙星特征拉曼峰的归属信息,建立快速、灵敏的定性分析方法,采用共焦显微激光拉曼技术,测得了恩诺沙星的拉曼散射图谱,并对其各个特征峰进行指认归属.实验表明,恩诺沙星的O-C-O在1 394.9 cm-1处的对称伸缩振动十分强烈.环丙基的CH2在3 005cm-1,3 069.4 cm-1处的对称与非对称伸缩振动非... 相似文献
17.
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs 总被引：9，自引：0，他引：9
K. KÜNG J.-L. RIOND M. WANNER 《Journal of veterinary pharmacology and therapeutics》1993,16(4):462-468
Rung, K., Riond, J.-L. & Wanner, M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J. vet
Four dogs were given 5 mg/kg body weight enrofloxacin intravenously (i.v.) and orally (p.o.) in a cross-over study. Plasma concentrations of the active ingredient enrofloxacin and its main metabolite ciprofloxacin were determined by a reversed phase liquid chromatographic method. Pharmacokinetic parameters of both substances were calculated by use of statistical moments and were compared to those of enrofloxacin described in the veterinary literature. Mean enrofloxacin t½λZ was 2.4 h, mean Cls was 27.1 ml/min-kg, and mean Vss was 7.0 1/kg. After i.v. and p.o. administration, concentrations of ciprofloxacin exceeding minimal inhibitory concentrations of several microorganisms were reached (Cmax = 0.2 ng/ml, max = 2.2 h after intravenous administration; Cmax = 0.2 (ig/ml, t max = 3.6 h after oral administration). A considerable part of the antimicrobial activity is due to ciprofloxacin, the main metabolite of enrofloxacin. 相似文献
Four dogs were given 5 mg/kg body weight enrofloxacin intravenously (i.v.) and orally (p.o.) in a cross-over study. Plasma concentrations of the active ingredient enrofloxacin and its main metabolite ciprofloxacin were determined by a reversed phase liquid chromatographic method. Pharmacokinetic parameters of both substances were calculated by use of statistical moments and were compared to those of enrofloxacin described in the veterinary literature. Mean enrofloxacin t
18.
Seguin MA Papich MG Sigle KJ Gibson NM Levy JK 《American journal of veterinary research》2004,65(3):350-356
OBJECTIVE: To determine the pharmacokinetics of enrofloxacin in neonatal kittens and compare the pharmacokinetics of enrofloxacin in young and adult cats. ANIMALS: 7 adult cats and 111 kittens (2 to 8 weeks old). PROCEDURE: A single dose of 5 mg of enrofloxacin/kg was administered to adults (i.v.) and kittens (i.v., s.c., or p.o.). Plasma concentrations of enrofloxacin and its active metabolite, ciprofloxacin, were determined. RESULTS: The half-life of enrofloxacin administered i.v. in 2-, 6-, and 8-week-old kittens was significantly shorter and its elimination rate significantly greater than that detected in adults. The apparent volumes of distribution were lower at 2 to 4 weeks and greater at 6 to 8 weeks. This resulted in lower peak plasma concentration (Cmax) at 6 to 8 weeks; however, initial plasma concentration was within the therapeutic range after i.v. administration at all ages. Compared with i.v. administration, s.c. injection of enrofloxacin in 2-week-old kittens resulted in similar Cmax, half-life, clearance, and area under the curve values. Enrofloxacin administered via s.c. injection was well absorbed in 6- and 8-week-old kittens, but greater clearance and apparent volume of distribution resulted in lower plasma concentrations. Oral administration of enrofloxacin resulted in poor bioavailability. CONCLUSIONS AND CLINICAL RELEVANCE: In neonatal kittens, i.v. and s.c. administration of enrofloxacin provided an effective route of administration. Oral administration of enrofloxacin in kittens did not result in therapeutic drug concentrations. Doses may need to be increased to achieve therapeutic drug concentrations in 6- to 8-week-old kittens. 相似文献
19.
